



# Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

**Corporate Office :** Mahendra Industrial Estate,  
Ground Floor, Plot No. 109-D, Road No. 29,  
Sion (East), Mumbai - 400 022. (India)  
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)  
Fax.: 022-2407 3462 / 2407 0144  
Email: admin@aartidrugs.com  
website: www.aartidrugs.com  
CIN No.:L37060MH1984PLC055433

## Press release for Jun'17

GST transition affected the domestic sales heavily in June quarter leading to decline in local sales to the extent of approximately 18%. However, there was good demand growth in export markets recording the volume growth of around 20.5% and the value growth of around 5.5% due to lower foreign exchange rate.

Consolidated Profit after tax for the quarter ended Jun'17 is 11.38 crores and Consolidated EBITDA for the quarter ended Jun'17 is 35.46 crores. Despite of the lower profit due to GST transition impact, Debt/Equity ratio was maintained at 1.13 as of Jun'17. Lower domestic sales affected the absolute gross contribution due to which operating margins were affected temporarily in this quarter.

Company is confident to face USFDA audit in recent future. Approvals for three of its products for European markets and marketing authorization of Zolpidem and Celecoxib tablets in UK and Ireland will positively impact the exports in future. Company has just commissioned centralized multiple effect evaporator systems to reduce the effluent streams, thus positively contributing towards the cleaner environment.

**For Aarti Drugs Limited**

**Harshit M. Savla**  
Jt. Managing Director

